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Early onset sepsis is defined as sepsis that occurs within the first 72 hours of birth. Late-onset sepsis (LOS)(onset of sepsis >72 hours of age 
or nosocomial sepsis) is an important cause of morbid-
ity and mortality in the neonatal intensive care unit 
(NICU)1 and occurs in approximately 10% of all neo-
nates, but can incidence can be as high as 25% among 
very low birth weight (VLBW) babies (birth weight 
<1500 g), and approaches 50% among extremely low 
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BACKGROUND AND OBJECTIVES: late onset sepsis (los)( onset of sepsis >72 hours of age or nosocomial sep-
sis) is an important cause of morbidity and mortality in the neonatal intensive care unit (nicu). thrombocytopenia 
is an important complication of sepsis. We investigated the incidence of thrombocytopenia in los patients and 
studied the influence of various parameters on platelet response. 
PATIENTS AND METHODS: infants born in the level 3 neonatal intensive care unit between January 2002 and 
december 2006 with documented los were included in this prospective study. multiple hemograms with 
platelet counts, bacterial blood culture and fungal blood culture were obtained in all patients. demographic and 
clinical data were compared between patients without thrombocytopenia and with mild, moderate and severe 
thrombocytopenia. duration of thrombocytopenia in relation to type of organism and mortality with respect to 
degree of thrombocytopenia were also studied. 
RESULTS: of 200 patients with culture-proven nosocomial sepsis, 119 (59.5%) patients developed thrombocyto-
penia (platelet count <150×109/l). in our series Klebsiella pneumoniae was the most frequently isolated organism 
(125/200, 62.5%) and the incidence of thrombocytopenia was 60.0% (75/125). however, the incidence of thrombo-
cytopenia was highest among patients who had concurrent bacterial and fungal sepsis (28/31, 90.3%). coagulase-
negative staphylococcal (cons) sepsis was present in 21 (10.5%) patients and the incidence of thrombocytopenia 
was 33.3%. isolated fungal sepsis was present only in 6 (3%) patients and the incidence of thrombocytopenia was 
66.0%. the incidence of thrombocytopenia was highest among preterm babies and low-birth weight (lbW) babies. 
twenty-seven percent (54/200) of babies presented with mild thrombocytopenia, 20% (40/200) presented with 
moderate thrombocytopenia, and 12.5%(25/200) developed severe thrombocytopenia. severity of thrombocyto-
penia was also directly related to the presence of necrotizing enterocolitis (nec) and disseminated intravascular 
coagulation (dic). the mortality rate was significantly associated with the degree of thrombocytopenia. 
CONCLUSION: los sepsis is an important risk factor for thrombocytopenia in the nicu. fungal and gram-
negative sepsis are frequently associated with a decreased platelet count. sepsis-induced thrombocytopenia is 
more common among lbW babies and preterm babies. the mortality rate is significantly related to degree of 
thrombocytopenia. 
birth weight (ELBW) babies (birth weight <1000 g).2 
Thrombocytopenia is an important complication of 
sepsis and can occur in 25% of patients admitted in 
the NICU.3 Early-onset thrombocytopenia develops 
in utero or within 72 hours of birth and has a varied 
etiology; late-onset thrombocytopenia is almost al-
ways caused by sepsis and necrotizing enterocolitis.4 
Virtually any organism capable of causing sepsis can 
induce thrombocytopenia. Riedler et al5 found an 80% 
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incidence of thrombocytopenia in gram-negative septi-
cemia and 65% incidence in gram-positive septicemia. 
In recent years fungal sepsis is increasingly associated 
with thrombocytopenia, especially in ELBW babies.6 
A fall in the platelet count is an early marker of sep-
sis and in fact can be used as a screening procedure for 
early detection of sepsis, especially in NICU settings. 
We designed a prospective study with the aim of 
learning the incidence of thrombocytopenia in blood-
culture positive sepsis and to study the influence of pa-
rameters like birthweight, gestational age and sepsis-
associated comorbidities like necrotizing enterocolitis 
(NEC) and disseminated intravascular coagulation 
(DIC) on platelet response. The duration of thrombo-
cytopenia in relation to type of organism and mortal-
ity with respect to degree of thrombocytopenia were 
also studied.
PATIENTS AND METHODS
The study was performed prospectively in the neonatol-
ogy unit of the Sher-I-Kashmir Institute Of Medical 
Sciences (SKIMS), which is a tertiary care centre, from 
January 2002 to December 2006 with prior approval by 
hospital ethical committee. Two hundred infants were 
included. All the babies were born in-house. An eligibil-
ity criterion was the presence of documented nosocomial 
LOS, defined by the presence of clinical features of sep-
sis along with a positive blood culture. Coagulase-nega-
tive staphylococcal (CoNS) sepsis was defined in our 
study as clinical signs of sepsis with a minimum of two 
positive blood cultures. For all patients in the nursery, it 
is our policy to do a routine baseline workup, which in-
cludes complete blood count (CBC), C-reactive protein 
(CRP) estimation, bacterial blood culture and fungal 
culture. Babies with early onset thrombocytopenia were 
excluded from the study. Infants with symptoms of sep-
sis (respiratory distress, poor feeding, lethargy, shock, 
disseminated intravascular coagulation, temperature 
instability) had a repeat sepsis evaluation performed. 
The evaluation CoNSisted of a CBC, including plate-
let indices, blood culture (bacterial and fungal), and 
serial CRP estimation. In case of clinical bleeding co-
agulogram with d-dimer ELISA was performed. Blood 
samples were drawn from peripheral venous puncture 
or through a central catheter. CBCs were performed by 
using Coulter counter (Sismax ST 3000). Serial platelet 
counts were performed in thrombocytopenic patients 
until platelet counts were normalized. Relevant data 
like sex, gestational age, birth weight, antenatal history, 
history of pregnancy-induced hypertension (PIH), 
mode of delivery, Apgar score, and hospital stay were 
recorded in all the study patients. Thrombocytopenia 
was defined as a platelet count of < 150×109/L and was 
classified by severity (mild if the platelet count was be-
tween 100 and <150×109/L, moderate if the count was 
between 50 and <100×109/L, and severe if the platelet 
count nadir was <50 ×109/L). Mortality was defined as 
death before discharge. Infants who were discharged to 
home were categorized as survivors.
Data is expressed as mean and standard deviation, 
and percentages. The intergroup comparison was done 
by the t test and ANOVA (F-test).
RESULTS
Two hundred cases of nosocomial sepsis were identi-
fied. Thrombocytopenia developed in 119 (59.5%) 
patients. Among the thrombocytopenic patients, 54 
(27%) were diagnosed as mild, 40 (20%) as moderate, 
and 25 (12.5%) as severe.
We compared neonatal data between the patients 
without thrombocytopenia and with mild, moder-
ate and severe thrombocytopenia (Table 1). The birth 
weight (grams) and gestational age (weeks) were sig-
nificantly lower among patients with moderate (1816 
[562] g, 33.73 [2.9] weeks) and severe thrombocytope-
nia (1484 [620] g, 31.84 [3.90] weeks) compared with 
patients with a normal platelet count (2473 [628] g, 
36.95 [2.77] weeks) and mild thrombocytopenia (2387 
[615] g, 36.09 [3.16] weeks) (P<.01). However, the dif-
ference in gestational age and birth weight between the 
patients with no thrombocytopenia and mild thrombo-
cytopenia was insignificant (P>.05). 
The incidence of NEC was more in patients with 
severe thrombocytopenia (6/25, 24%) and moder-
ate thrombocytopenia (8/40, 20%) than in patients 
with mild thrombocytopenia (1/54, 5.90%), and no 
thrombocytopenia (2/81, 11.80%). (P<.01). Similarly 
DIC was more commonly found in patients with se-
vere thrombocytopenia (22/25, 88.0%) and moderate 
thrombocytopenia (10/40, 25.0%) (P<.01). Mortality 
was significantly more in patients with DIC. The pres-
ence of DIC among survivors was 17/159 versus non-
survivors 19/41, P<.01). No differences were observed 
in maternal age, parity, gender, mode of delivery, Apgar 
score, or TORCH positivity among the groups.
Of the 200 patients with documented nosocomial 
sepsis, 125 (62.5%) were infected with Klebsiella pneu-
moniae and 75 (60.0%) developed thrombocytopenia 
(Table 2). In 31 patients (15.5%) combined fungal 
(Candida in all patients) and bacterial sepsis (Klebsiella 
20, CoNS 8, Enterococcus 2, E coli 1, S aureus 1) was 
documented. All the patients in this group were LBW 
(1170 [890]). The incidence of thrombocytopenia 
was significantly higher in this group (28/31), 90.3%) 
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(P<.01). The incidence of CoNS sepsis in our study 
population was 10.5% (21/200) and among these 7 
(33.3%) patients had at least 1 episode of thrombo-
cytopenia. Six patients (3%) in our series had a posi-
tive culture for Candida albicans, and the incidence of 
thrombocytopenia in those patients was 66.6% (4/6). 
All were ELBW babies. Other organisms isolated 
were E coli (5/200, 2.5%), S aureus (7/200, 3.5%) and 
Enterococcus (5/200, 2.5%).
The mean duration of thrombocytopenia was signifi-
cantly higher in patients of combined bacterial and fun-
gal sepsis (P<.05) as compared to isolated fungal sepsis 
and Klebsiella sepsis. The mean duration of thrombocy-
topenia was lowest in CoNS sepsis (Figure 1).
The overall mortality rate in our study population 
was 20.5% (41/200) (Figure 2). Mortality was sig-
nificantly higher in patients with thrombocytopenia 
(32/119, 26.8%) than in the non-thrombocytopenic 
Characteristics
No 
thrombocytopenia 
(n=81)
Thrombocytopenia (n=119, 59.5%)
P value
Mild (n=54, 27%) Moderate (n=40, 20%)
Severe 
(n=25, 12.5%)
Gestational age 
(weeks) 36.95 (2.77) 36.09 (3.16) 33.73 (2.99) 31.84 (3.90) <.01
Birth weight (grams) 2473 (628) 2387 (615) 1816 (562) 1484 (620) <.01
Gender
NS   Male 39 (39%) 23 (23%) 27 (27%) 11 (11%)
   Female 42 (42%) 31 (31%) 13 (13%) 14 (14%)
Maternal age (years) 30.5 (4) 31.4 (3.8) 30.4 (6) 32.2 (4) NS
Mode of delivery
NS   NVD 55/81 (62.9%) 38/54 (70.3%) 25/40 (62.5%) 12/25 (48%)
   LSCS 26/81 (32%) 16/54 (29.6%) 15/40 (37.5%) 10/25 (52%)
Low birth weight 39 (32.8%) 25 (28.6%) 34 (28.6%) 21 (17.6%) <.01
TORCH +ve - - 2 (66.7%) 1 (33.3%) NS
DiC - 4/54 (7.4%) 10/40 (25%) 22/25 (88%) <.01
NeC 2/81 (2.46%) 1/54 (1.85%) 8/40 (20%) 6/25 (24%) <.01
Mortality 9/81 (11%) 8/54 (14.8%) 8/40 (20%) 16/25 (64%) <.01
Table 1. Demographic and clinical characteristics of the study groups.
Data are mean (standard deviation) or number (percentages). NVD: normal vaginal delivery, LSCS: lower segment cesarean section, TORCH: toxoplasmosis, rubella, 
cytomegalovirus, herpex simplex
Table 2. Organism-specific response to thrombocytopenia.
Type of organism No thrombocytopenia
Thrombocytopenia
Mild Moderate Severe
Klebsiella 50/125 (40.0%) 39/125 (31.2%) 23/125 (18.4%) 13/125
Mixed fungal and  
bacterial sepsis 3/31 (9.6%) 9/31 (29.0%) 9/31 (29.0%) (10.4%)
CoNS 14/21 (66.6%) 3/21 (14.2%) 3/21 (14.2%) 10/31 (32.2%)
S aureus 5/7 (71.4%) 1/7 (14.2%) 1/21 (14.2%) 1/21 (4.76%)
Candida 2/6 (33.3%) --- 3/6 (50.0%) --- 
enterococcus 3/5 (60.0%) 1/5 (20.0%) 1/5 (20.0%) 1/6 (16.6%)
e coli 4/5 (80.0%) 1/5 (20.0%) --- ---
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group (9/81, 11.1%) (P<.01). Mortality was highest in 
patients with severe thrombocytopenia (16/25, 64.0%) 
as compared to patients with moderate thrombocy-
topenia (8/40, 20.0%) and mild thrombocytopenia 
(8/54, 14.8%).
DISCUSSION 
Platelets are among the least studied cells in sepsis, 
yet it has been well described for more than 30 years 
that patients with sepsis often have low platelet counts 
and that intravenous injection of lipopolysaccharides 
(LPS) into mice induces rapid thrombocytopenia.7 
Within a few minutes of the intravenous injection of 
lipopolysaccharide (LPS) into mice, platelets accumu-
late primarily in the liver and in lungs.8 Although the 
mechanisms of activation and recruitment remain un-
clear, they are thought to be related to the cascade of 
endogenous mediators released rather than to a direct 
response to LPS.
 We conducted this study to see the incidence of 
late-onset thrombocytopenia among inborn babies 
with documented nosocomial sepsis irrespective of ges-
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Figure 1. Mean duration of thrombocytopenia among different 
organisms.
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Figure 2. Mortality in different study groups.
tational age and birth weight. We observed that 59.5% 
of babies with documented sepsis developed a platelet 
count <150×109/L with 27% presenting with mild, 
20% moderate and 12% with severe thrombocytopenia. 
LOS is an important risk factor for thrombocytopenia 
and can involve up to 80% of septic babies.9 In a study 
by Naeme et al10 on adult patients, thrombocytopenia 
occurred in about 75% of patients. Furthermore, we 
observed that the incidence of thrombocytopenia was 
more common in LBW babies (67.1%) as compared to 
normal birth weight babies (48.1%, P<.05). The former 
group developed a lower platelet nadir. This was similar 
to observation of many authors.11,12
Profound thrombocytopenia occurs in humans 
with sepsis and in mice administered LPS. Growing 
evidence indicates that, in addition to their hemostatic 
role, platelets play an important role in linking innate 
and adaptive immune responses.13 Platelets express a 
family of signaling receptors, known as Toll-like recep-
tors (TLRs) and they recognize a variety of molecular 
structures found on bacteria, viruses, and fungi.14-16 
Recognition of these “danger” molecules leads to TLR 
signaling, which in turn leads to the production of sev-
eral proinflammatory cytokines.17 It appears that TLRs 
are sentinels of the innate immune system and are es-
sential for the eventual stimulation of adaptive immu-
nity against invading microorganisms. TLR expression 
on platelets has a role to play during infectious inflam-
mation and atherosclerotic vascular disease. This is per-
haps best exemplified by the clinical observation of se-
vere thrombocytopenia associated with sepsis.18 Some 
septic babies also develop thrombocytopenia on the ba-
sis of DIC, but most have thrombocytopenia without 
laboratory evidence of DIC. In a study of septic adults 
by Naeme et al,10 DIC was present in a small minority, 
and these were a subgroup who had a platelet count of 
less than 50 000/L. Our data revealed that DIC was as-
sociated in almost 25% of patients and the majority of 
them belonged to severe thrombocytopenia group.
NEC is an important risk factor for late-onset throm-
bocytopenia. Ververidis et al19 showed that thrombocy-
topenia was a common finding in NEC. We confirmed 
the same association. The incidence of NEC was signifi-
cantly higher in patients with moderate (20%) and se-
vere thrombocytopenia (24%). We demonstrated an as-
sociation of fungal sepsis and gram negative (Klebsiella) 
sepsis with thrombocytopenia, an association that has 
been confirmed in many studies.20 In fact, we observed 
that the incidence of thrombocytopenia was highest 
among the patients with combined fungal and bacterial 
sepsis (90.3%) (most of whom had Klebsiella isolated 
from blood), followed by isolated fungal sepsis (66.6%) 
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and Klebsiella sepsis (60.0%). CoNS sepsis was less fre-
quently associated with thrombocytopenia in our series 
(33.3%). Padovani et al21 reported 26 VLBW neonates 
who had fungal sepsis and noted that 19 (73%) present-
ed with thrombocytopenia. In fact, it is recommended 
to start empiric antifungal treatment when thrombocy-
topenia is seen in ELBW infants who are clinically septic 
with a nosocomial infection while awaiting culture re-
ports.22 Similarly, gram-negative sepsis is an important 
cause of thrombocytopenia in humans.
Thrombocytopenia is itself associated with increased 
mortality in neonates23,24 as well as in adult septic pa-
tients.25 We observed that morality was significantly 
more common in thrombocytopenic patients (26.8%) 
than patients with a normal platelet count (11.1%) 
(P<.01). Mortality was higher among patients with se-
vere thrombocytopenia.
Our study indicates that a large proportion (59.5%) 
of infants with nosocomial sepsis develop thrombo-
cytopenia and the severity of thrombocytopenia is di-
rectly related to gestational age and birth weight. We 
were able to confirm that mixed fungal and bacterial 
sepsis were more frequently associated with thrombo-
cytopenia with a significantly higher mean duration of 
thrombocytopenia. We demonstrated a significantly 
higher mortality in thrombocytopenic group than in 
the non-thrombocytopenic group. A larger controlled 
study could be undertaken in resource poor settings 
where the burden of sepsis and low birth weight is high, 
to test whether profound and persistent thrombocyto-
penia can be used as a surrogate marker for fungal sep-
sis. The study also gives some justification for empiric 
antifungal therapy in situations where fungal cultures 
are unavailable or unaffordable.
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